Equities analysts predict that Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) will post sales of $8.12 million for the current quarter, according to Zacks. Two analysts have issued estimates for Enanta Pharmaceuticals’ earnings, with the highest sales estimate coming in at $8.70 million and the lowest estimate coming in at $7.53 million. Enanta Pharmaceuticals posted sales of $13.98 million during the same quarter last year, which would indicate a negative year over year growth rate of 41.9%. The business is scheduled to report its next quarterly earnings results on Monday, August 14th.

On average, analysts expect that Enanta Pharmaceuticals will report full year sales of $8.12 million for the current financial year, with estimates ranging from $75.36 million to $75.69 million. For the next fiscal year, analysts expect that the business will report sales of $82.63 million per share, with estimates ranging from $80.78 million to $84.48 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Enanta Pharmaceuticals.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Monday, May 8th. The biotechnology company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.10. The firm had revenue of $9 million for the quarter, compared to analyst estimates of $9.19 million. Enanta Pharmaceuticals had a negative return on equity of 4.94% and a negative net margin of 28.68%. The business’s revenue for the quarter was down 30.8% on a year-over-year basis. During the same quarter last year, the firm posted ($0.09) earnings per share.

Several equities research analysts have weighed in on the company. BidaskClub downgraded Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. Zacks Investment Research downgraded Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, June 21st. JMP Securities upgraded Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 price objective on the stock in a report on Tuesday, July 11th. Finally, ValuEngine upgraded Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Enanta Pharmaceuticals has a consensus rating of “Buy” and an average target price of $30.75.

Shares of Enanta Pharmaceuticals (ENTA) traded up 2.19% during trading on Friday, hitting $37.27. The stock had a trading volume of 212,563 shares. The company’s 50 day moving average price is $32.65 and its 200 day moving average price is $31.68. The stock’s market cap is $711.22 million. Enanta Pharmaceuticals has a 12 month low of $20.79 and a 12 month high of $37.98.

TRADEMARK VIOLATION WARNING: “Analysts Anticipate Enanta Pharmaceuticals, Inc. (ENTA) Will Post Quarterly Sales of $8.12 Million” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/07/16/analysts-anticipate-enanta-pharmaceuticals-inc-enta-will-post-quarterly-sales-of-8-12-million.html.

Hedge funds have recently bought and sold shares of the stock. Thrivent Financial for Lutherans acquired a new stake in Enanta Pharmaceuticals during the fourth quarter valued at approximately $250,000. State Board of Administration of Florida Retirement System purchased a new position in Enanta Pharmaceuticals during the fourth quarter valued at $204,000. Adams Diversified Equity Fund Inc. increased its position in Enanta Pharmaceuticals by 2.9% in the first quarter. Adams Diversified Equity Fund Inc. now owns 24,500 shares of the biotechnology company’s stock valued at $755,000 after buying an additional 700 shares during the last quarter. Public Sector Pension Investment Board increased its position in Enanta Pharmaceuticals by 10.0% in the fourth quarter. Public Sector Pension Investment Board now owns 9,900 shares of the biotechnology company’s stock valued at $332,000 after buying an additional 900 shares during the last quarter. Finally, Guggenheim Capital LLC purchased a new position in Enanta Pharmaceuticals during the fourth quarter valued at $1,024,000. 67.32% of the stock is owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.